risperidone has been researched along with Intellectual Disability in 83 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Intellectual Disability: Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
| Excerpt | Relevance | Reference |
|---|---|---|
| "62 subjects with intellectual disability underwent to a 2-arm, parallel group pragmatic trial of olanzapine and risperidone with balanced randomisation and blind assessment of outcome at 4, 8, 12, 16, 20 and 24 weeks after a switch (cross-tapering) from a 24-week treatment with FGAs." | 9.15 | Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. ( Amore, M; Bertelli, M; Rossi, M; Tamborini, S; Villani, D, 2011) |
| "We report on an open-label, naturalistic study using risperidone to treat disruptive behaviors and self-injury in children with Down syndrome, severe intellectual disability, and comorbid autism spectrum disorders (DS+ASDs)." | 9.13 | Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. ( Capone, GT; Goyal, P; Grados, M; Kammann, H; Smith, B, 2008) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 9.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 9.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 8.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 7.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| "A patient with comorbid intellectual disability, catatonic schizophrenia, and recurrent oneiroid state of consciousness improved on long-acting risperidone and remains well at the three-year follow-up." | 7.81 | Effectiveness of long-acting risperidone in a patient with comorbid intellectual disability, catatonic schizophrenia, and oneiroid syndrome. ( Alessi, MC; Angeletti, G; Callovini, G; Criscuolo, S; Del Casale, A; Ferri, VR; Girardi, P; Janiri, D; Kotzalidis, GD; Massolo, AC; Rapinesi, C; Serata, D, 2015) |
| "We report several cases in which patients with autistic disorder with mental retardation who received risperidone experienced urinary incontinence." | 7.80 | Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation. ( Imasaka, Y; Iwata, K; Kumazaki, H; Mimura, M; Tomoda, A; Watanabe, K, 2014) |
| "Two children aged 11 and 10 years, diagnosed with autism and mental retardation, have developed new-onset diurnal and nocturnal enuresis respectively on their first and second weeks of risperidone monotherapy (1." | 7.74 | Risperidone-induced enuresis in two children with autistic disorder. ( Hergüner, S; Mukaddes, NM, 2007) |
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 7.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 7.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| "Young patients with intellectual disability (ID) have both diagnostic and therapeutic challenges." | 5.72 | Top-Up Clozapine for Risperidone LAI-Related Acute Dystonia and TR Bipolar in an Adolescent with ID- ( Alamiri, B; Naguy, A; Pridmore, S; Singh, A, 2022) |
| "Risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia." | 5.30 | Risperidone for aggression and self-injurious behavior in adults with mental retardation. ( Cohen, SA; Ihrig, K; Kerrick, JM; Lott, RS, 1998) |
| "Many autistic patients with mental retardation have difficulties with explosivity and aggression." | 5.30 | Risperidone and explosive aggressive autism. ( Barnhill, LJ; Horrigan, JP, 1997) |
| "62 subjects with intellectual disability underwent to a 2-arm, parallel group pragmatic trial of olanzapine and risperidone with balanced randomisation and blind assessment of outcome at 4, 8, 12, 16, 20 and 24 weeks after a switch (cross-tapering) from a 24-week treatment with FGAs." | 5.15 | Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. ( Amore, M; Bertelli, M; Rossi, M; Tamborini, S; Villani, D, 2011) |
| "We report on an open-label, naturalistic study using risperidone to treat disruptive behaviors and self-injury in children with Down syndrome, severe intellectual disability, and comorbid autism spectrum disorders (DS+ASDs)." | 5.13 | Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. ( Capone, GT; Goyal, P; Grados, M; Kammann, H; Smith, B, 2008) |
| "The results of this post hoc analysis of affective symptoms of DBDs using data from a previously published randomized, double-blind clinical comparison of risperidone and placebo in the treatment of children with DBDs and subaverage intelligence suggest that risperidone was effective in treating the factors of explosive irritability; agitated, expansive, grandiose; and depression." | 5.12 | Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. ( Biederman, J; Faraone, SV; Mick, E; Pandina, G; Spencer, T; Wozniak, J, 2006) |
| "To determine whether risperidone is effective in reducing symptoms of disruptive behaviors (such as aggression, impulsivity, defiance of authority figures, and property destruction) associated with conduct disorder, oppositional defiant disorder, and disruptive behavior disorder-not otherwise specified in children with subaverage IQs." | 5.10 | Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. ( Aman, M; Binder, C; Carroll, A; Fisman, S; Snyder, R; Turgay, A, 2002) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 5.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 5.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| "Antipsychotics, particularly risperidone, appear to be effective in reducing problem behaviors in children with intellectual disability." | 4.93 | Pharmacotherapy for mental health problems in people with intellectual disability. ( Findling, RL; Ji, NY, 2016) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 4.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 3.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| "A patient with comorbid intellectual disability, catatonic schizophrenia, and recurrent oneiroid state of consciousness improved on long-acting risperidone and remains well at the three-year follow-up." | 3.81 | Effectiveness of long-acting risperidone in a patient with comorbid intellectual disability, catatonic schizophrenia, and oneiroid syndrome. ( Alessi, MC; Angeletti, G; Callovini, G; Criscuolo, S; Del Casale, A; Ferri, VR; Girardi, P; Janiri, D; Kotzalidis, GD; Massolo, AC; Rapinesi, C; Serata, D, 2015) |
| "We report several cases in which patients with autistic disorder with mental retardation who received risperidone experienced urinary incontinence." | 3.80 | Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation. ( Imasaka, Y; Iwata, K; Kumazaki, H; Mimura, M; Tomoda, A; Watanabe, K, 2014) |
| "Two children aged 11 and 10 years, diagnosed with autism and mental retardation, have developed new-onset diurnal and nocturnal enuresis respectively on their first and second weeks of risperidone monotherapy (1." | 3.74 | Risperidone-induced enuresis in two children with autistic disorder. ( Hergüner, S; Mukaddes, NM, 2007) |
| "Atypical antipsychotics, especially clozapine and olanzapine, have been increasingly associated with weight gain and other adverse metabolic events (diabetes mellitus, hyperlipidemia) in non-mentally retarded populations." | 3.73 | Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. ( Ball, MP; Bodfish, JW; Heeth, WL; Mahorney, SL; McKee, JR, 2005) |
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 3.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 3.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| "In people with intellectual disability (ID) and challenging behaviour, antipsychotics (AP) are often used off-label and for a long period." | 3.01 | Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial. ( Beumer, S; Hamers, P; Maes-Festen, D; Oppewal, A, 2021) |
| "Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies." | 2.72 | A crossover study of risperidone in children, adolescents and adults with mental retardation. ( Fleming, KK; Hellings, JA; Marquis, JG; Reese, RM; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2006) |
| "Risperidone was also associated with significantly greater improvement than placebo on all other Nisonger Child Behavior Rating Form subscales at endpoint, as well as on the Aberrant Behavior Checklist subscales for irritability, lethargy/social withdrawal, and hyperactivity; the Behavior Problems Inventory aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; and the Clinical Global Impression change score." | 2.70 | Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. ( Aman, MG; De Smedt, G; Derivan, A; Findling, RL; Lyons, B, 2002) |
| "Risperidone was given in daily doses ranging from 0." | 2.69 | Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. ( Buitelaar, JK, 2000) |
| "Risperidone (1-8 mg/day) was associated with a 50 percent or greater reduction in at least one target behavior frequency in 61 percent of patients." | 2.68 | Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. ( Cohen, SA; Kerrick, JM; Lott, RS, 1996) |
| "Risperidone was significantly superior to placebo in its effect on the Aberrant Behaviour Checklist and the Clinical Global Impression." | 2.67 | Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. ( Buttiëns, M; Dierick, G; Geutjens, J; Heylen, S; Sieben, G; Thiry, P; Vanden Borre, R; Vermote, R, 1993) |
| "Probably pseudohypoaldosteronism was a coincidental finding in this girl with a CDK13 mutation, but because only limited information is known about CDK13-related disorders, further investigation could be more informative to clarify this presentation." | 2.61 | One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature. ( Ayman, A; Kremer, AK; van den Akker, M; Yakubov, R, 2019) |
| " They responded well to the reduction in dosage or to withdrawal of the apparent causing agent." | 2.49 | [Medication-related oculogyric crises: a description of four cases and a review of the literature]. ( Campistol, J; Darling, A; Perez-Duenas, B; Poo, P, 2013) |
| " Although there are some reports in literature, the side effect profile in this population remains poorly defined and there is a need to raise awareness among clinicians across specialties." | 1.91 | Recognising side effects of antipsychotics in children with intellectual disabilities. ( Anand, G; Lee, J; Shepperd, R; Smith, M, 2023) |
| "Young patients with intellectual disability (ID) have both diagnostic and therapeutic challenges." | 1.72 | Top-Up Clozapine for Risperidone LAI-Related Acute Dystonia and TR Bipolar in an Adolescent with ID- ( Alamiri, B; Naguy, A; Pridmore, S; Singh, A, 2022) |
| "There were significant gaps in adverse effect monitoring in this cohort." | 1.51 | Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities. ( Javaheri, KR; McLennan, JD, 2019) |
| "A 55-year-old woman with a history of mental retardation and infantile psychosis is hospitalized for worsening of her psychiatric symptoms." | 1.43 | [Case report: Neuroleptic malignant syndrome and diagnostic difficulties]. ( Khouri, C; Logerot, S; Mallaret, M; Planès, S; Villier, C, 2016) |
| "She also exhibited precocious puberty and growth hormone deficiency and required treatment for improving final height." | 1.40 | Endocrinological anomalies in a patient with 12q14 microdeletion syndrome. Completing phenotype of this exceptional short stature condition. ( Marco, FC; Nso-Roca, AP; Ricote, JM; Ruiz, MJ, 2014) |
| "The patient had profound mental retardation, had an IQ in the range of less than 20 to 25, and was nonverbal." | 1.34 | Risperidone for the treatment of fecal smearing in a developmentally disabled adult. ( Brahm, NC; Brown, RC; Farmer, KC, 2007) |
| " During the subsequent week, rates of problem behavior typically decreased without reinstating the prior dosage of medication." | 1.34 | Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates. ( Dornbusch, K; Rapp, JT; Swanson, G, 2007) |
| "The structural background of mental retardation, the function of the affected cerebral structures, is not completely clarified." | 1.32 | [Experience with Risperidone in the treatment of institutionalized mentally retarded patients, with special reference to treatment of aggressive states]. ( Fehér, L; Hal, V, 2004) |
| ""B" was an 11-year-old girl with mild mental retardation and aggression who was treated with risperidone 1 mg per day." | 1.32 | Risperidone-induced obsessive-compulsive symptoms in two children. ( Avci, A; Diler, RS; Scahill, L; Yolga, A, 2003) |
| "Risperidone was able to reduce the aggressive behavior in this patient." | 1.31 | Risperidone for controlling aggressive behavior in a mentally retarded child: a case report. ( Intaprasert, S; Maneeton, N; Srisurapanont, M, 2001) |
| "Many autistic patients with mental retardation have difficulties with explosivity and aggression." | 1.30 | Risperidone and explosive aggressive autism. ( Barnhill, LJ; Horrigan, JP, 1997) |
| "Weight gain was observed in 5 of 6 patients, with a median increase of 5." | 1.30 | Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. ( Armenteros, J; Munoz-Silva, DM; Pataki, C; Perry, R; Silva, RR, 1997) |
| "Risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia." | 1.30 | Risperidone for aggression and self-injurious behavior in adults with mental retardation. ( Cohen, SA; Ihrig, K; Kerrick, JM; Lott, RS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (14.46) | 18.2507 |
| 2000's | 39 (46.99) | 29.6817 |
| 2010's | 27 (32.53) | 24.3611 |
| 2020's | 5 (6.02) | 2.80 |
| Authors | Studies |
|---|---|
| Beumer, S | 1 |
| Hamers, P | 1 |
| Oppewal, A | 1 |
| Maes-Festen, D | 1 |
| Naguy, A | 1 |
| Pridmore, S | 1 |
| Singh, A | 1 |
| Alamiri, B | 1 |
| Hodgins, GE | 1 |
| Winsor, K | 1 |
| Barnhill, J | 1 |
| Lee, J | 1 |
| Shepperd, R | 1 |
| Smith, M | 1 |
| Anand, G | 1 |
| Yakubov, R | 1 |
| Ayman, A | 1 |
| Kremer, AK | 1 |
| van den Akker, M | 1 |
| Espadas, C | 1 |
| Ballester, P | 1 |
| Londoño, AC | 1 |
| Almenara, S | 1 |
| Aguilar, V | 1 |
| Belda, C | 1 |
| Pérez, E | 1 |
| Peiró, AM | 1 |
| Lambrechts, S | 1 |
| Devriendt, K | 1 |
| Vogels, A | 1 |
| Ramerman, L | 2 |
| Hoekstra, PJ | 2 |
| de Kuijper, G | 2 |
| Scheers, T | 1 |
| Vink, M | 1 |
| Vrijmoeth, P | 1 |
| Javaheri, KR | 1 |
| McLennan, JD | 1 |
| Gnanavel, S | 1 |
| Nso-Roca, AP | 1 |
| Marco, FC | 1 |
| Ricote, JM | 1 |
| Ruiz, MJ | 1 |
| Adler, BA | 1 |
| Wink, LK | 1 |
| Early, M | 1 |
| Shaffer, R | 1 |
| Minshawi, N | 1 |
| McDougle, CJ | 3 |
| Erickson, CA | 1 |
| Kumazaki, H | 1 |
| Watanabe, K | 1 |
| Imasaka, Y | 1 |
| Iwata, K | 1 |
| Tomoda, A | 1 |
| Mimura, M | 1 |
| Kiliçaslan, F | 1 |
| Bayazit, H | 1 |
| Kandemir, H | 1 |
| Çalik, M | 1 |
| Kandemir, SB | 1 |
| Guler, K | 1 |
| Serata, D | 1 |
| Rapinesi, C | 2 |
| Kotzalidis, GD | 2 |
| Alessi, MC | 1 |
| Janiri, D | 1 |
| Massolo, AC | 1 |
| Ferri, VR | 1 |
| Criscuolo, S | 1 |
| Callovini, G | 1 |
| Angeletti, G | 1 |
| Girardi, P | 2 |
| Del Casale, A | 2 |
| Ji, NY | 1 |
| Findling, RL | 2 |
| Khouri, C | 1 |
| Planès, S | 1 |
| Logerot, S | 1 |
| Villier, C | 1 |
| Mallaret, M | 1 |
| Sacco, M | 1 |
| De Giorgi, R | 1 |
| Giardini, M | 1 |
| D'Andreagiovanni, M | 1 |
| Carlino, N | 1 |
| Brugnoli, R | 1 |
| Grau, K | 1 |
| Plener, PL | 1 |
| Gahr, M | 1 |
| Denzer, C | 1 |
| Freudenmann, RW | 1 |
| Scahill, L | 2 |
| Aman, MG | 3 |
| McCracken, JT | 1 |
| Vitiello, B | 1 |
| Pasini, A | 1 |
| D'Agati, E | 1 |
| Casarelli, L | 1 |
| Curatolo, P | 1 |
| Romeo, R | 1 |
| Knapp, M | 2 |
| Tyrer, P | 2 |
| Crawford, M | 1 |
| Oliver-Africano, P | 2 |
| Dickens, S | 1 |
| Ahmed, Z | 1 |
| Bouras, N | 2 |
| Cooray, S | 1 |
| Deb, S | 1 |
| Hare, M | 1 |
| Meade, M | 1 |
| Reece, B | 1 |
| Bhaumik, S | 1 |
| Harley, D | 1 |
| Piachaud, J | 1 |
| Regan, A | 1 |
| Ade Thomas, D | 1 |
| Karatela, S | 1 |
| Rao, B | 1 |
| Dzendrowskyj, T | 1 |
| Lenôtre, L | 1 |
| Watson, J | 1 |
| Valdovinos, MG | 3 |
| Bailey, L | 1 |
| Taylor, SL | 1 |
| Amore, M | 1 |
| Bertelli, M | 1 |
| Villani, D | 1 |
| Tamborini, S | 1 |
| Rossi, M | 1 |
| Janowsky, DS | 1 |
| Hu, Q | 1 |
| Buneviciute, J | 1 |
| Davis, JM | 1 |
| Budisteanu, M | 1 |
| Papuc, SM | 1 |
| Tutulan-Cunita, A | 1 |
| Budisteanu, B | 1 |
| Arghir, A | 1 |
| Usta, MG | 1 |
| Tufan, AE | 1 |
| Cüceloğlu, EA | 1 |
| Gandal, MJ | 1 |
| Sisti, J | 1 |
| Klook, K | 1 |
| Ortinski, PI | 1 |
| Leitman, V | 1 |
| Liang, Y | 1 |
| Thieu, T | 1 |
| Anderson, R | 1 |
| Pierce, RC | 1 |
| Jonak, G | 1 |
| Gur, RE | 1 |
| Carlson, G | 1 |
| Siegel, SJ | 1 |
| Sharma, V | 1 |
| Biswas, DD | 1 |
| Banga, A | 1 |
| Connor, DF | 1 |
| Pringsheim, T | 1 |
| Gorman, D | 1 |
| Darling, A | 1 |
| Poo, P | 1 |
| Perez-Duenas, B | 1 |
| Campistol, J | 1 |
| De Smedt, G | 1 |
| Derivan, A | 1 |
| Lyons, B | 1 |
| Turgay, A | 2 |
| Binder, C | 2 |
| Snyder, R | 2 |
| Fisman, S | 2 |
| Aman, M | 2 |
| Carroll, A | 1 |
| Levitas, A | 1 |
| Yoo, JH | 1 |
| Williams, DC | 1 |
| Napolitano, DA | 1 |
| Peyton, RT | 1 |
| Baer, DM | 1 |
| Schroeder, SR | 6 |
| Diler, RS | 1 |
| Yolga, A | 1 |
| Avci, A | 1 |
| Vercammen, L | 1 |
| Buyse, GM | 1 |
| Proost, JE | 1 |
| Van Hove, JL | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Hal, V | 1 |
| Fehér, L | 1 |
| Gharabawi, GM | 1 |
| Correia Filho, AG | 1 |
| Bodanese, R | 1 |
| Silva, TL | 1 |
| Alvares, JP | 1 |
| Rohde, LA | 1 |
| McKee, JR | 1 |
| Bodfish, JW | 1 |
| Mahorney, SL | 1 |
| Heeth, WL | 1 |
| Ball, MP | 1 |
| Hellings, JA | 4 |
| Zarcone, JR | 4 |
| Reese, RM | 3 |
| Gaughan, E | 1 |
| Marquis, JG | 1 |
| Fleming, KK | 1 |
| Reyes, M | 1 |
| Croonenberghs, J | 1 |
| Augustyns, I | 1 |
| Eerdekens, M | 1 |
| Biederman, J | 1 |
| Mick, E | 1 |
| Faraone, SV | 1 |
| Wozniak, J | 1 |
| Spencer, T | 1 |
| Pandina, G | 1 |
| Brahm, NC | 1 |
| Farmer, KC | 1 |
| Brown, RC | 1 |
| Hergüner, S | 2 |
| Mukaddes, NM | 2 |
| Niederhofer, H | 1 |
| Rapp, JT | 1 |
| Swanson, G | 1 |
| Dornbusch, K | 1 |
| Matson, JL | 1 |
| Wilkins, J | 1 |
| Ruedrich, SL | 1 |
| Swales, TP | 1 |
| Rossvanes, C | 1 |
| Diana, L | 1 |
| Arkadiev, V | 1 |
| Lim, K | 1 |
| Capone, GT | 1 |
| Goyal, P | 1 |
| Grados, M | 1 |
| Smith, B | 1 |
| Kammann, H | 1 |
| Trollor, JN | 1 |
| Somerville, ER | 1 |
| Somerville, HM | 1 |
| Purdon, SE | 1 |
| Lit, W | 1 |
| Labelle, A | 1 |
| Jones, BD | 1 |
| Vanden Borre, R | 1 |
| Vermote, R | 1 |
| Buttiëns, M | 1 |
| Thiry, P | 1 |
| Dierick, G | 1 |
| Geutjens, J | 1 |
| Sieben, G | 1 |
| Heylen, S | 1 |
| Levin, GM | 1 |
| Lazowick, AL | 1 |
| Powell, HS | 1 |
| Simon, EW | 1 |
| Blubaugh, KM | 1 |
| Pippidis, M | 1 |
| Lott, RS | 2 |
| Kerrick, JM | 2 |
| Cohen, SA | 2 |
| Horrigan, JP | 1 |
| Barnhill, LJ | 1 |
| Demb, HB | 1 |
| Khan, BU | 1 |
| Perry, R | 1 |
| Pataki, C | 1 |
| Munoz-Silva, DM | 1 |
| Armenteros, J | 1 |
| Silva, RR | 1 |
| Ihrig, K | 1 |
| Dartnall, NA | 1 |
| Holmes, JP | 1 |
| Morgan, SN | 1 |
| Hässler, F | 2 |
| Fegert, JM | 1 |
| Buitelaar, JK | 2 |
| Williams, H | 1 |
| Clarke, R | 1 |
| Martin, J | 1 |
| Holt, G | 1 |
| Cohen, S | 1 |
| Glazewski, R | 1 |
| Khan, S | 1 |
| Khan, A | 1 |
| Van Bellinghen, M | 1 |
| De Troch, C | 1 |
| van der Gaag, RJ | 1 |
| Cohen-Kettenis, P | 1 |
| Melman, CT | 1 |
| Hammock, R | 1 |
| Levine, WR | 1 |
| Maneeton, N | 1 |
| Intaprasert, S | 1 |
| Srisurapanont, M | 1 |
| Crandall, K | 2 |
| Wallace, D | 1 |
| Friedlander, R | 1 |
| Lazar, S | 1 |
| Klancnik, J | 1 |
| Marquis, J | 1 |
| Fleming, K | 1 |
| Shores, R | 1 |
| Williams, D | 1 |
| Jagadheesan, K | 1 |
| Nizamie, SH | 1 |
| Buchmann, J | 1 |
| Bohne, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398] | 12 participants (Actual) | Observational | 2013-04-29 | Terminated | |||
| The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years[NCT00266552] | Phase 3 | 118 participants (Actual) | Interventional | Completed | |||
| The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years[NCT00250354] | Phase 3 | 110 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors[NCT00065273] | Phase 3 | 50 participants | Interventional | 1998-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for risperidone and Intellectual Disability
| Article | Year |
|---|---|
Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Child; Conduct Disorder; Humans; In | 2022 |
One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature.
Topics: CDC2 Protein Kinase; Chelating Agents; DNA Mutational Analysis; Female; Humans; Infant; Intellectual | 2019 |
Pharmacotherapy for mental health problems in people with intellectual disability.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Ce | 2016 |
Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2012 |
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Ch | 2013 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia Dise | 2004 |
[Psychopharmacological therapy of self-injurious behavior in mentally retarded individuals].
Topics: Adult; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Intellectual Disability; Male | 1999 |
23 trials available for risperidone and Intellectual Disability
| Article | Year |
|---|---|
Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial.
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Humans; Intellectual Disabili | 2021 |
Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Child; Double-Blind Method; Drug Administration Sched | 2019 |
The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.
Topics: Adult; Aggression; Antipsychotic Agents; Combined Modality Therapy; Cost-Benefit Analysis; Double-Bl | 2009 |
Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities.
Topics: Adult; Aggression; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Evid | 2010 |
Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; L | 2011 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
Topics: Antipsychotic Agents; Child; Child Behavior Disorders; Dopamine Antagonists; Female; Humans; Intelle | 2002 |
Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
Topics: Analysis of Variance; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chi | 2002 |
Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation.
Topics: Adult; Antipsychotic Agents; Attention; Autistic Disorder; Behavior Therapy; Bipolar Disorder; Discr | 2003 |
Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2005 |
Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; | 2005 |
A crossover study of risperidone in children, adolescents and adults with mental retardation.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Studies; D | 2006 |
Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Co | 2006 |
Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.
Topics: Affective Symptoms; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Depre | 2006 |
Antipsychotic drugs for aggression in intellectual disability.
Topics: Aggression; Antipsychotic Agents; Haloperidol; Humans; Intellectual Disability; Risperidone | 2008 |
Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Autistic Disorder; Central Nervous | 2008 |
Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, | 1993 |
Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance.
Topics: Adult; Aged; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Prognosis | 1996 |
Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Female; Hospitalization; Humans; Intellectual D | 2000 |
Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Child; Child Behavior Disorders; Double-Blind | 2001 |
A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; B | 2001 |
Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Stud | 2001 |
Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures.
Topics: Adolescent; Adult; Aged; Aggression; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Do | 2001 |
52 other studies available for risperidone and Intellectual Disability
| Article | Year |
|---|---|
Top-Up Clozapine for Risperidone LAI-Related Acute Dystonia and TR Bipolar in an Adolescent with ID-
Topics: Adolescent; Antipsychotic Agents; Clozapine; Dystonia; Dystonic Disorders; Humans; Intellectual Disa | 2022 |
Recognising side effects of antipsychotics in children with intellectual disabilities.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug-Related Side Effects and Adverse Reactio | 2023 |
Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability.
Topics: Adult; Autism Spectrum Disorder; Cohort Studies; Comorbidity; Female; Humans; Intellectual Disabilit | 2020 |
Low-Dose Aripiprazole and Risperidone for Treating Problem Behavior in Children With Pitt-Hopkins Syndrome.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Facies; Female; Humans; Hyperventilation; Int | 2018 |
Changes in Health-Related Quality of Life in People With Intellectual Disabilities Who Discontinue Long-Term Used Antipsychotic Drugs for Challenging Behaviors.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Child; Double-Blind Method; Female; Humans; Intellect | 2019 |
Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Canada; Community Mental Health Services; Drug-Re | 2019 |
Smith-Magneis syndrome: behavioural phenotype mimics ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 2014 |
Endocrinological anomalies in a patient with 12q14 microdeletion syndrome. Completing phenotype of this exceptional short stature condition.
Topics: Antipsychotic Agents; Body Height; Child; Child Behavior Disorders; Chromosome Deletion; Dwarfism; E | 2014 |
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child D | 2015 |
Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation.
Topics: Adult; Aged; Antipsychotic Agents; Autistic Disorder; Fecal Incontinence; Female; Humans; Intellectu | 2014 |
Motor Weakness Related to Risperidone.
Topics: Antipsychotic Agents; Child Behavior Disorders; Child, Preschool; Humans; Intellectual Disability; M | 2015 |
Effectiveness of long-acting risperidone in a patient with comorbid intellectual disability, catatonic schizophrenia, and oneiroid syndrome.
Topics: Adult; Ambroxol; Antipsychotic Agents; Brain; Dreams; Follow-Up Studies; Humans; Intellectual Disabi | 2015 |
[Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
Topics: Antipsychotic Agents; Dantrolene; Female; Humans; Intellectual Disability; Middle Aged; Muscle Relax | 2016 |
Effectiveness of switching from oral ziprasidone to risperidone in a patient with comorbid autistic disorder, profound intellectual disability, Gilbert syndrome, and exacerbation of psychosis.
Topics: Adult; Antipsychotic Agents; Autistic Disorder; Comorbidity; Gilbert Disease; Humans; Intellectual D | 2016 |
Mild Hypothermia in a Child with Low-Dose Risperidone.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Comb | 2017 |
Beware of over-interpreting negative trials.
Topics: Adult; Antipsychotic Agents; Awareness; Clinical Trials as Topic; Humans; Intellectual Disability; P | 2008 |
Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome.
Topics: Abnormalities, Multiple; Adolescent; Aggression; Animals; Antipsychotic Agents; Chromosome Deletion; | 2010 |
Examining risperidone use in those diagnosed with autism 1 year after FDA approval.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Autistic Disorder; Child; Humans; Intellectua | 2010 |
Minimum effective and relapse-associated doses of risperidone and olanzapine in aggressive, intellectually disabled adults.
Topics: Adult; Age Factors; Aggression; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; I | 2011 |
Novel clinical finding in MECP2 duplication syndrome.
Topics: Child; Child Development; Chromosomes, Human, X; Cognitive Behavioral Therapy; Early Intervention, E | 2011 |
Diphenhydramine use in the treatment of risperidone-induced sialorrhea.
Topics: Adolescent; Antipsychotic Agents; Diphenhydramine; Dose-Response Relationship, Drug; Follow-Up Studi | 2012 |
GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.
Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Explorato | 2012 |
Antecollis, lingual dystonia, and mutism secondary to risperidone.
Topics: Antipsychotic Agents; Child; Dystonia; Female; Humans; Intellectual Disability; Mutism; Risperidone; | 2012 |
Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Compulsive Behavior; Humans; Intellectual Disabi | 2012 |
Reader response to, "Effects of risperidone on aberrant behavior in persons with developmental disabilities: I. A double-blind crossover study using multiple measures".
Topics: Antipsychotic Agents; Cross-Over Studies; Double-Blind Method; Humans; Intellectual Disability; Ment | 2003 |
Risperidone-induced obsessive-compulsive symptoms in two children.
Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Female; Huma | 2003 |
Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy.
Topics: Adult; Antipsychotic Agents; Creatine Kinase; Dopamine; Female; Fever; Hallucinations; Humans; Intel | 2003 |
[Experience with Risperidone in the treatment of institutionalized mentally retarded patients, with special reference to treatment of aggressive states].
Topics: Adult; Aged; Aggression; Antipsychotic Agents; Dopamine Antagonists; Female; Humans; Hungary; Instit | 2004 |
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Comorbidi | 2005 |
Risperidone for the treatment of fecal smearing in a developmentally disabled adult.
Topics: Adult; Antipsychotic Agents; Behavior Control; Disabled Persons; Feces; Hepatitis B; Humans; Intelle | 2007 |
Risperidone-induced enuresis in two children with autistic disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Child; Diurnal Enuresis; Humans; Intellect | 2007 |
Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2).
Topics: Abnormalities, Multiple; Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder wi | 2007 |
Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Female; Human | 2007 |
Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Body Weight; Dibenzothiazepines; Dose-Resp | 2008 |
Risperidone-induced double incontinence.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Fecal Incontinence; Female; Humans; Inte | 2008 |
Antipsychotics in individuals with intellectual disability.
Topics: Antipsychotic Agents; Behavior Control; Haloperidol; Humans; Intellectual Disability; Randomized Con | 2008 |
Risperidone in the treatment of pervasive developmental disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Perv | 1994 |
Neuroleptic malignant syndrome with risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Intellectual Disability; Male | 1996 |
Substituting traditional antipsychotics with risperidone for individuals with mental retardation.
Topics: Adult; Aged; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Dyskinesia, Drug-I | 1996 |
Risperidone and explosive aggressive autism.
Topics: Activities of Daily Living; Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; | 1997 |
Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
Topics: Aggression; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Huma | 1996 |
Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
Topics: Adult; Aggression; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Drug Adminis | 1997 |
Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.
Topics: Adolescent; Anger; Child; Child Development Disorders, Pervasive; Dopamine Antagonists; Female; Huma | 1997 |
Risperidone for aggression and self-injurious behavior in adults with mental retardation.
Topics: Adult; Aggression; Antipsychotic Agents; Behavior Therapy; Combined Modality Therapy; Female; Humans | 1998 |
Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.
Topics: Adult; Autistic Disorder; Compulsive Behavior; Dopamine Antagonists; Female; Gynecomastia; Humans; I | 1999 |
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Follow-Up St | 2000 |
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
Topics: Aggression; Antipsychotic Agents; Diet; Dose-Response Relationship, Drug; Energy Intake; Humans; Int | 2001 |
Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Humans; Intellectual Disability; Male; Middle Ag | 2001 |
Risperidone for controlling aggressive behavior in a mentally retarded child: a case report.
Topics: Aggression; Antipsychotic Agents; Child; Humans; Intellectual Disability; Male; Risperidone | 2001 |
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; M | 2001 |
Risperidone-induced Pisa syndrome.
Topics: Adult; Antipsychotic Agents; Dystonic Disorders; Female; Humans; Intellectual Disability; Posture; P | 2002 |
[Possibilities and limits of treatment of aggressive behavior in patients with mental retardation with risperidone].
Topics: Adult; Aggression; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Intellectual Disability; | 2002 |